Evidence map›Paper›PMID 37333821›Full record

ArticleFrontiers in oncology2023

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma.

Eleanor Jayawant, Arran Pack, Heather Clark, Emma Kennedy, Ankur Ghodke, John Jones, Chris Pepper, Andrea Pepper, Simon Mitchell

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Computational modelling of aggressive B-cell lymphoma.Biochemical Society transactions · 2025
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Eleanor JayawantDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Arran PackDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Heather ClarkDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Emma KennedyDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Ankur GhodkeDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
John JonesDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Chris PepperDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Andrea PepperDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Simon MitchellDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
Brighton and Sussex Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Improving treatments for Diffuse Large B-Cell Lymphoma (DLBCL) is challenged by the vast heterogeneity of the disease. Nuclear factor-κB (NF-κB) is frequently aberrantly activated in DLBCL. Transcriptionally active NF-κB is a dimer containing either RelA, RelB or cRel, but the variability in the composition of NF-κB between and within DLBCL cell populations is not known. Results: Here we describe a new flow cytometry-based analysis technique termed "NF-κB fingerprinting" and demonstrate its applicability to DLBCL cell lines, DLBCL core-needle biopsy samples, and healthy donor blood samples. We find each of these cell populations has a unique NF-κB fingerprint and that widely used cell-of-origin classifications are inadequate to capture NF-κB heterogeneity in DLBCL. Computational modeling predicts that RelA is a key determinant of response to microenvironmental stimuli, and we experimentally identify substantial variability in RelA between and within ABC-DLBCL cell lines. We find that when we incorporate NF-κB fingerprints and mutational information into computational models we can predict how heterogeneous DLBCL cell populations respond to microenvironmental stimuli, and we validate these predictions experimentally. Discussion: Our results show that the composition of NF-κB is highly heterogeneous in DLBCL and predictive of how DLBCL cells will respond to microenvironmental stimuli. We find that commonly occurring mutations in the NF-κB signaling pathway reduce DLBCL's response to microenvironmental stimuli. NF-κB fingerprinting is a widely applicable analysis technique to quantify NF-κB heterogeneity in B cell malignancies that reveals functionally significant differences in NF-κB composition within and between cell populations.

Indexed as

computational biologyDLCBLlymphomamath modelingNFkBsystems biologyTME (tumor microenvironment)

Identifiers

PMID37333821
PMCPMC10272839
OpenAlexW4379229552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.